Joanne E. Filicko

Dr. Joanne E. Filicko

Transplant Surgery | Oncology
2211 Chapel Avenue, 
Cherry Hill, NJ 
Accepting New Patients
Offers Telehealth
2211 Chapel Avenue, 
Cherry Hill, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joanne Filicko is an Oncologist and a Transplant Surgeon in Cherry Hill, New Jersey. Dr. Filicko is rated as an Experienced provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Multiple Myeloma, and Bone Marrow Transplant. Dr. Filicko is currently accepting new patients.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Drexel University College Of Medicine
Residency
Thomas Jefferson University Hospitals
Specialties
Transplant Surgery
Oncology
Licenses
Internal Medicine in PA
Board Certifications
Medical Oncology
Hematology
Fellowships
Thomas Jefferson University Hospitals
Hospital Affiliations
Jefferson Cherry Hill Hospital
Jefferson Methodist Hospital
Jefferson Stratford Hospital
Jefferson Washington Township Hospital
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Sidney Kimmel Comprehensive Cancer Center — Cherry Hill
2211 Chapel Avenue, Cherry Hill, NJ 08002
Other Locations
Medical Oncology & Infusion Suite - 900 Medical Center Drive
900 Medical Center Drive, Suite 200, Sewell, NJ 08080
1101 Chestnut Street, Floor 14, Philadelphia, PA 19107

Additional Areas of Focus

Dr. Filicko has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Aplastic Anemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Drug, Radiation, Genetic
Study Phase: Phase 2
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: Sirolimus, Azacitidine
Study Phase: Phase 2
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug, Radiation, Procedure, Other, Biological
Study Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Allogeneic Lymphocytes
Study Phase: Phase 2
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 02, 2025
Intervention Type: Drug, Radiation, Biological, Procedure
Study Phase: Phase 1
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Biological, Procedure, Radiation
Study Phase: Phase 2
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Procedure, Genetic
Study Drugs: Bendamustine, Ofatumumab, Carboplatin, Etoposide
Study Phase: Phase 1/Phase 2
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Device
Study Phase: Phase 2
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: April 29, 2025
Intervention Type: Drug
Study Phase: Early Phase 1
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: April 24, 2025
Intervention Type: Drug, Radiation, Other, Biological, Procedure
Study Drugs: Fludarabine, T Cell-Depleted Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil
Study Phase: Phase 2
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drugs: Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Study Phase: Phase 2
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Radiation, Drug, Biological, Device, Procedure
Study Drugs: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Donor Lymphocyte Infusion
Study Phase: Phase 2
View 11 Less Clinical Trials

26 Total Publications

The Heart of the Matter: Cardiac Toxicity in Allogenic Stem Cell Transplant with Post-Transplant Cyclophosphamide.
The Heart of the Matter: Cardiac Toxicity in Allogenic Stem Cell Transplant with Post-Transplant Cyclophosphamide.
Journal: Transplantation and cellular therapy
Published: June 15, 2025
Similar Doctors
Advanced in Acute Myelomonocytic Leukemia
Dr. Michael M. Mikhail
Oncology | Hematology
Advanced in Acute Myelomonocytic Leukemia
Dr. Michael M. Mikhail
Oncology | Hematology

Christiana Care Health Services Inc

4755 Ogletown Stanton Rd, 
Newark, DE 
 (32.6 miles away)
Languages Spoken:
English
See accepted insurances

Michael Mikhail is an Oncologist and a Hematologist in Newark, Delaware. Dr. Mikhail is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Paget Disease of the Breast, Hemangioma Thrombocytopenia Syndrome, Adult Immune Thrombocytopenia, and Thrombocytopenia.

Advanced in Acute Myelomonocytic Leukemia
Dr. Stephen A. Shore
Hematology Oncology | Hematology | Oncology
Advanced in Acute Myelomonocytic Leukemia
Dr. Stephen A. Shore
Hematology Oncology | Hematology | Oncology

Consultants In Medical Oncology And Hematology PC

3855 W Chester Pike, Cancer Center Ground Floor, 
Newtown Square, PA 
 (13.6 miles away)
610-492-5900
Languages Spoken:
English
See accepted insurances

Stephen Shore is a Hematologist Oncology specialist and a Hematologist in Newtown Square, Pennsylvania. Dr. Shore is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Lung Cancer, Thrombocytopenia, and Familial Colorectal Cancer.

Margaret T. Kasner
Advanced in Acute Myelomonocytic Leukemia
Dr. Margaret T. Kasner
Hematology Oncology | Oncology | Palliative Medicine
Advanced in Acute Myelomonocytic Leukemia
Dr. Margaret T. Kasner
Hematology Oncology | Oncology | Palliative Medicine

Jefferson Cancer - Honickman Center

1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
 (0.1 miles away)
215-955-8874
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Margaret Kasner is an Oncologist and a Palliative Medicine provider in Philadelphia, Pennsylvania. Dr. Kasner is rated as a Distinguished provider by MediFind in the treatment of Acute Myelomonocytic Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kasner is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Filicko's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 45 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile